United States Artificial Coma Market Insight
Published: 05 June 2026 | Report Format: Electronic (PDF)
The United States Artificial Coma (Medically Induced Coma) Market is projected to grow at a CAGR of around 6.8%, driven by the increasing incidence of traumatic brain injuries, rising prevalence of refractory status epilepticus, growing demand for advanced neurocritical care, expanding ICU admissions, and continuous advancements in anesthesia and sedation management technologies.
United States Artificial Coma (Medically Induced Coma) Market Forecasts to 2035
- The United States Artificial Coma (Medically Induced Coma) Market Size Was Estimated at USD 1.48 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 6.8% from 2025 to 2035.
- The United States Artificial Coma (Medically Induced Coma) Market Size is Expected to Reach around USD 2.86 Billion by 2035.
Notable Insights for the United States Artificial Coma (Medically Induced Coma) Market
- Segmentation Based on Drug Type, the Propofol-Based Sedation segment held a dominant position in the United States Artificial Coma Market in 2025 with nearly 42% share, supported by rapid onset, predictable recovery, and widespread ICU utilization.
- Segmentation Based on Application, the Traumatic Brain Injury Management segment accounted for approximately 39% share in 2025, driven by increasing emergency admissions and the growing adoption of neuroprotective intensive care protocols.
- The market is supported by major critical care pharmaceutical suppliers, including Fresenius Kabi and Pfizer Inc.; Fresenius Kabi reported approximately EUR 8.41 billion revenue in 2024, reflecting its strong presence in injectable anesthetics and critical care medicines.
- Pfizer Inc. reported approximately USD 62.0 billion revenue in 2025, while Baxter International Inc. generated approximately USD 15.1 billion revenue, highlighting the financial strength of companies participating in anesthesia and critical care therapeutics.
Download the eBook (ToC)
Research Used to Analyze the United States Artificial Coma (Medically Induced Coma) Market
This study employs a combination of primary and secondary research methodologies to analyze the United States Artificial Coma (Medically Induced Coma) Market. Primary research includes interviews and discussions with neurologists, intensivists, anesthesiologists, hospital administrators, pharmaceutical manufacturers, ICU specialists, distributors, and industry experts. Secondary research involves company annual reports, clinical journals, government healthcare databases, regulatory publications, investor presentations, and reputable market sources. Market size estimations are derived using both top-down and bottom-up approaches, while data triangulation and validation techniques ensure the accuracy and reliability of market forecasts, competitive assessments, and industry trends.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States artificial coma market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Artificial Coma (Medically Induced Coma) Market
• Pfizer Inc.
• Fresenius Kabi
• Baxter International Inc.
• B. Braun Medical Inc.
• Hikma Pharmaceuticals PLC
• Viatris Inc.
• AbbVie Inc.
• Piramal Critical Care
• Teva Pharmaceutical Industries Ltd.
• ICU Medical Inc.
Recent Developments:
- In September 2025, Fresenius Kabi expanded its U.S. critical care injectable portfolio through the launch of advanced anesthesia and sedation products designed for hospital and ICU settings.
- In July 2025, Pfizer Inc. collaborated with leading U.S. hospital networks to strengthen critical care treatment access and optimize sedation management protocols in intensive care environments.
Market Segmentation:
United States Artificial Coma (Medically Induced Coma) Market, By Drug Type
• Propofol
• Midazolam
• Pentobarbital
• Thiopental
• Dexmedetomidine
• Others
United States Artificial Coma (Medically Induced Coma) Market, By Application
• Traumatic Brain Injury Management
• Refractory Status Epilepticus
• Stroke Management
• Neurosurgical Procedures
• Critical Care Sedation
• Others
United States Artificial Coma (Medically Induced Coma) Market, By End User
• Hospitals
• Specialty Neurology Centers
• Ambulatory Surgical Centers
• Academic Medical Centers
United States Artificial Coma (Medically Induced Coma) Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Direct Procurement
Expert Views:
The United States Artificial Coma (Medically Induced Coma) Market is expected to witness strong growth through 2035, supported by increasing demand for neurocritical care, rising traumatic brain injury cases, expanding ICU infrastructure, and continuous innovation in anesthetic and sedation therapies. Strategic collaborations and product launches are anticipated to further strengthen market expansion during the forecast period.
Author: Aditi and Govind By Spherical Insights and Consulting